---
title: "UBS lowers the target price for SINO BIOPHARM to 11 yuan, rating it as \"Buy\""
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280955823.md"
description: "UBS has lowered the target price for SINO BIOPHARM to 11 yuan, maintaining a \"Buy\" rating. The report pointed out that last year the company's revenue was 31.8 billion yuan, a year-on-year increase of 10.3%, which was below expectations; net profit was 2.3 billion yuan, a year-on-year increase of 22%, also below expectations. The gross profit margin rose to 82.1%. Management expects double-digit growth in both revenue and profit this year. Although the earnings per share forecast for this year has been raised by 9.4%, the earnings per share forecasts for 2027 and 2028 have been lowered due to lower expectations for generic drug revenue"
datetime: "2026-03-30T04:28:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280955823.md)
  - [en](https://longbridge.com/en/news/280955823.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280955823.md)
generator: "portal-rs"
---

# UBS lowers the target price for SINO BIOPHARM to 11 yuan, rating it as "Buy"

UBS published a research report indicating that SINO BIOPHARM (01177.HK) had a revenue of RMB 31.8 billion last year, an increase of 10.3% year-on-year, which was below expectations; net profit reached RMB 2.3 billion, a year-on-year increase of 22%, also below expectations; gross profit margin increased by 0.6 percentage points year-on-year to 82.1%. Management expects that driven by the continuous growth of innovative products, revenue and profit will achieve double-digit growth this year.

The bank raised its earnings per share forecast for SINO BIOPHARM this year by 9.4%, but lowered its earnings per share forecasts for 2027 and 2028 due to lower expectations for revenue and profitability from generic drugs. Additionally, it lowered the company's target price from HKD 12.2 to HKD 11 and reiterated its "Buy" rating

### Related Stocks

- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [516610.CN](https://longbridge.com/en/quote/516610.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [002393.CN](https://longbridge.com/en/quote/002393.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [25317.HK](https://longbridge.com/en/quote/25317.HK.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)

## Related News & Research

- [Sino Biopharma rebrands as SBP Group, targets global expansion via direct commercial rollout and partnerships](https://longbridge.com/en/news/296447837.md)
- [Sino Biopharm says NMPA clears TQF6422 obesity drug candidate for clinical trial](https://longbridge.com/en/news/296603125.md)
- [Sino Biopharm declares 2026 interim dividend of HKD 0.07 a share](https://longbridge.com/en/news/296324109.md)
- [SBP GROUP  Interim Net Profit Rises 1.4% YoY to RMB3.43B; Div 7 HK Cents](https://longbridge.com/en/news/296327356.md)
- [Sino Biopharma rebrands global operations under SBP Group identity](https://longbridge.com/en/news/296347598.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**